Abstract
Background: Antidepressant medication is a major cornerstone in treatment of mood and anxiety disorders. Numerous substances are available on the market; however, only 60% of treated patients show sufficient response to medication and side effects are common. Lengthy trials are not uncommon until the optimized drug and dose is found and unfortunately, no valid predictors to match the ‘right’ drug to the ‘right’ patient exist nowadays. Genetic factors are thought to be involved as evidenced by numerous pharmacogenetic studies. This comprehensive review summarizes the most interesting findings and discusses clinical implications of pharmacogenetic results.
Methods: We reviewed available literature on pharmacogenetics of antidepressant response and side effects until summer 2011 using the PubMed database.
Results: Promising findings exist for several variants in candidate genes involved in the pharmacokinetics or pharmacodynamics of antidepressants. These include association findings in the serotonin transporter gene (5-HTT), serotonin receptor genes, a gene coding an efflux pump in the blood-brain-barrier (ABCB1), and genes involved in the HPA axis. Promising candidate genes increasing risk for side effects include some of the genes associated with treatment response and cytochrome P450 genes.
Conclusion: A high number of studies on pharmacogenetics of antidepressants have been published during the past decades. However, contradictory results still limit clinical use of these findings. Future studies should include functional analyses and consider gene-gene and gene-environment interactions. This will aid in facilitating a future use of pharmacogenetics in clinical practice, likely leading to improved patient care.
Keywords: Pharmacogenetics, antidepressant, response, side-effects, polymorphism, 5-HTTLPR, ABCB1, serotonin, FKBP5, gene-environment interactions
Current Pharmaceutical Design
Title:Genetics and Personalized Medicine in Antidepressant Treatment
Volume: 18 Issue: 36
Author(s): Katarina Gvozdic, Eva J. Brandl, Danielle L. Taylor and Daniel J. Muller
Affiliation:
Keywords: Pharmacogenetics, antidepressant, response, side-effects, polymorphism, 5-HTTLPR, ABCB1, serotonin, FKBP5, gene-environment interactions
Abstract: Background: Antidepressant medication is a major cornerstone in treatment of mood and anxiety disorders. Numerous substances are available on the market; however, only 60% of treated patients show sufficient response to medication and side effects are common. Lengthy trials are not uncommon until the optimized drug and dose is found and unfortunately, no valid predictors to match the ‘right’ drug to the ‘right’ patient exist nowadays. Genetic factors are thought to be involved as evidenced by numerous pharmacogenetic studies. This comprehensive review summarizes the most interesting findings and discusses clinical implications of pharmacogenetic results.
Methods: We reviewed available literature on pharmacogenetics of antidepressant response and side effects until summer 2011 using the PubMed database.
Results: Promising findings exist for several variants in candidate genes involved in the pharmacokinetics or pharmacodynamics of antidepressants. These include association findings in the serotonin transporter gene (5-HTT), serotonin receptor genes, a gene coding an efflux pump in the blood-brain-barrier (ABCB1), and genes involved in the HPA axis. Promising candidate genes increasing risk for side effects include some of the genes associated with treatment response and cytochrome P450 genes.
Conclusion: A high number of studies on pharmacogenetics of antidepressants have been published during the past decades. However, contradictory results still limit clinical use of these findings. Future studies should include functional analyses and consider gene-gene and gene-environment interactions. This will aid in facilitating a future use of pharmacogenetics in clinical practice, likely leading to improved patient care.
Export Options
About this article
Cite this article as:
Gvozdic Katarina, J. Brandl Eva, L. Taylor Danielle and J. Muller Daniel, Genetics and Personalized Medicine in Antidepressant Treatment, Current Pharmaceutical Design 2012; 18 (36) . https://dx.doi.org/10.2174/138161212803523617
DOI https://dx.doi.org/10.2174/138161212803523617 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vasoactive Renal Factors and the Progression of Diabetic Nephropathy
Current Pharmaceutical Design Unsafe Abortion: The Silent Endemic; An Avoidable Cause of Maternal Mortality. A Review
Current Women`s Health Reviews Central Nervous System Agents Used as Trypanosoma cruzi Infection Chemotherapy: Phenothiazines and Related Compounds
Current Medicinal Chemistry - Anti-Infective Agents Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Necrotizing Enterocolitis: Clinical Features, Histopathological Characteristics, and Genetic Associations
Current Pediatric Reviews Therapeutic Hypothermia in Brain Injuries and Related Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Ambulatory Blood Pressure and Diabetes: Targeting Nondipping
Current Diabetes Reviews Current Outcomes and Considerations in Hypoplastic Left Heart Syndrome
Current Pediatric Reviews The Relationship Between 24-Hour Indicators and Mortality in Patients with Exertional Heat Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets Cardioprotective Effects and <i>in-silico</i> Antioxidant Mechanism of L-Ergothioneine in Experimental Type-2 Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Dopamine and Vascular Dynamics Control: Present Status and Future Perspectives
Current Neurovascular Research Improvement of Nerve Fiber Density in Fibromyalgia Patients Treated with IVIg
Current Rheumatology Reviews Neurochemical and Neuropharmacological Aspects of Circadian Disruptions: An Introduction to Asynchronization
Current Neuropharmacology Prevalence and Risk Factors of Vitamin D Deficiency in Critically Ill Patients
Inflammation & Allergy - Drug Targets (Discontinued) Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design Intravenous Antihypertensives within Cardiovascular-Based Continuity of Care
Current Vascular Pharmacology Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) Potential Novel Anxiolytic Drugs
Current Pharmaceutical Design